Abstract
Locally advanced non–small cell lung cancer is a heterogeneous disease with typically poor outcomes. Select patients may benefit from the integration of surgery, whereas patients with bulky, multistation, or contralateral (N3) mediastinal involvement are managed with definitive chemoradiation. Attempts to improve outcomes through induction, consolidation, or maintenance chemotherapy or radiation dose escalation have not demonstrated a survival benefit. Current research efforts focus on the integration of novel systemic agents that exploit tumor-specific driver mutations, augment antitumor immune response, or enhance radiation sensitivity.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 45-57 |
| Number of pages | 13 |
| Journal | Hematology/Oncology Clinics of North America |
| Volume | 31 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 1 2017 |
Fingerprint
Keywords
- Chemoradiation
- Locally advanced disease
- Non–small cell lung cancer
ASJC Scopus subject areas
- Hematology
- Oncology
Cite this
Treatment of Locally Advanced Non–Small Cell Lung Cancer. / Tam, Kit; Daly, Megan E; Kelly, Karen.
In: Hematology/Oncology Clinics of North America, Vol. 31, No. 1, 01.02.2017, p. 45-57.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Treatment of Locally Advanced Non–Small Cell Lung Cancer
AU - Tam, Kit
AU - Daly, Megan E
AU - Kelly, Karen
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Locally advanced non–small cell lung cancer is a heterogeneous disease with typically poor outcomes. Select patients may benefit from the integration of surgery, whereas patients with bulky, multistation, or contralateral (N3) mediastinal involvement are managed with definitive chemoradiation. Attempts to improve outcomes through induction, consolidation, or maintenance chemotherapy or radiation dose escalation have not demonstrated a survival benefit. Current research efforts focus on the integration of novel systemic agents that exploit tumor-specific driver mutations, augment antitumor immune response, or enhance radiation sensitivity.
AB - Locally advanced non–small cell lung cancer is a heterogeneous disease with typically poor outcomes. Select patients may benefit from the integration of surgery, whereas patients with bulky, multistation, or contralateral (N3) mediastinal involvement are managed with definitive chemoradiation. Attempts to improve outcomes through induction, consolidation, or maintenance chemotherapy or radiation dose escalation have not demonstrated a survival benefit. Current research efforts focus on the integration of novel systemic agents that exploit tumor-specific driver mutations, augment antitumor immune response, or enhance radiation sensitivity.
KW - Chemoradiation
KW - Locally advanced disease
KW - Non–small cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=84998879861&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84998879861&partnerID=8YFLogxK
U2 - 10.1016/j.hoc.2016.08.009
DO - 10.1016/j.hoc.2016.08.009
M3 - Review article
VL - 31
SP - 45
EP - 57
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
SN - 0889-8588
IS - 1
ER -